Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 7/20 | 0.47 |
| ▸ | CDK1 | P06493 | 6/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721618 | 0.86 | PDPK1 (0.56) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL5509118 | 0.86 | PDPK1 (0.56) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL28004538 | 0.85 | PDPK1 (0.54) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL7165321 | 0.83 | PDPK1 (0.53) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL28731074 | 0.82 | PDPK1 (0.59) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL48131 | 0.81 | PDPK1 (0.50) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL24995361 | 0.80 | CDK2 (0.41) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL4364347 | 0.80 | CDK1 (0.49) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL13269009 | 0.80 | PDPK1 (0.49) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL13268765 | 0.80 | PDPK1 (0.49) | PDPK1GDACDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220243244-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2022-08-04 | — | — | US | claimed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | claimed |
| WO-2021072167-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-15 | — | — | WO | claimed |
| WO-2012099630-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A RETROVIRUS INFECTION | UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | claimed |
| US-7223849-B1 | Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth | GENESENSE TECHNOLOGIES INC. (CA) | 2007-05-29 | — | — | US | claimed |
| US-7067497-B2 | Modulation of telomere length by oligonucleotides having a G-core sequence | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| WO-2004011613-A2 | COMPOSITION & METHODS FOR TREATMENT AND SCREENING | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-6566514-B1 | Antisense oligonucleotides for use in the treatment of tumors | GENESENSE TECHNOLOGIES INC. (CA) | 2003-05-20 | — | — | US | claimed |
| WO-2026101887-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125412-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735626-A1 | USING APERTURES TO CAPTURE POLYNUCLEOTIDES ON PARTICLES | Illumina, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735624-A1 | CAPTURING AND AMPLIFYING POLYNUCLEOTIDES USING PARTICLES | Illumina, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20040259100-A1 | Methods and compositions for whole genome amplification and genotyping | ILLUMINA, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040259106-A1 | Methods and compositions for whole genome amplification and genotyping | ILLUMINA, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040014096-A1 | Dual-labeled nucleotides | STRATAGENE | 2004-01-22 | — | — | US | disclosed |
| WO-2003087302-A2 | DUAL-LABELED NUCLEOTIDES | STRATAGENE (US) | 2003-10-23 | — | — | WO | disclosed |
| US-4086347-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIEDEMIC AGENTS, HYPOTENSIVES | BOEHRINGER MANNHEIM GMBH (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014096-A1 | Dual-labeled nucleotides | NT5C2, DUT, NT5E | PDPK1 4196/4885GDA 116/4885CDK2 1937/4885 |
| US-20260125412-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | PNP, MTAP, SLC35B2 | PDPK1 1004/4885GDA 796/4885CDK2 1700/4885 |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | POLN, PCNA, POLB | PDPK1 3823/4885GDA 621/4885CDK2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.